A detailed history of Hgk Asset Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hgk Asset Management Inc holds 137,698 shares of BMY stock, worth $8.13 Million. This represents 1.34% of its overall portfolio holdings.

Number of Shares
137,698
Previous 131,022 5.1%
Holding current value
$8.13 Million
Previous $5.44 Million 30.95%
% of portfolio
1.34%
Previous 1.06%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$39.66 - $51.75 $264,770 - $345,483
6,676 Added 5.1%
137,698 $7.13 Million
Q2 2024

Aug 06, 2024

BUY
$40.25 - $52.99 $271,969 - $358,053
6,757 Added 5.44%
131,022 $5.44 Million
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $406,342 - $460,713
8,469 Added 7.31%
124,265 $6.74 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $774,855 - $924,616
15,983 Added 16.01%
115,796 $5.94 Million
Q3 2023

Oct 20, 2023

BUY
$57.89 - $64.73 $476,376 - $532,663
8,229 Added 8.99%
99,813 $5.79 Million
Q2 2023

Aug 02, 2023

BUY
$63.71 - $70.74 $211,644 - $234,998
3,322 Added 3.76%
91,584 $5.86 Million
Q1 2023

Apr 28, 2023

BUY
$65.71 - $74.53 $993,535 - $1.13 Million
15,120 Added 20.67%
88,262 $6.12 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $23,283 - $27,570
340 Added 0.47%
73,142 $5.26 Million
Q3 2022

Oct 18, 2022

SELL
$0.13 - $76.84 $997 - $589,670
-7,674 Reduced 9.54%
72,802 $5.18 Million
Q2 2022

Jul 29, 2022

SELL
$72.62 - $79.98 $831,281 - $915,531
-11,447 Reduced 12.45%
80,476 $6.2 Million
Q1 2022

May 04, 2022

SELL
$61.48 - $73.72 $814,302 - $976,421
-13,245 Reduced 12.59%
91,923 $6.71 Million
Q4 2021

Feb 01, 2022

BUY
$53.63 - $62.52 $628,221 - $732,359
11,714 Added 12.53%
105,168 $6.56 Million
Q3 2021

Oct 28, 2021

BUY
$59.17 - $69.31 $382,474 - $448,019
6,464 Added 7.43%
93,454 $5.53 Million
Q2 2021

Jul 30, 2021

BUY
$61.91 - $67.42 $259,526 - $282,624
4,192 Added 5.06%
86,990 $5.81 Million
Q1 2021

Apr 15, 2021

BUY
$59.34 - $66.74 $313,018 - $352,053
5,275 Added 6.8%
82,798 $5.23 Million
Q4 2020

Jan 08, 2021

BUY
$57.74 - $65.43 $325,769 - $369,156
5,642 Added 7.85%
77,523 $4.81 Million
Q3 2020

Nov 05, 2020

SELL
$57.43 - $63.64 $1.51 Million - $1.68 Million
-26,353 Reduced 26.83%
71,881 $4.33 Million
Q2 2020

Aug 10, 2020

SELL
$54.82 - $64.09 $1.36 Million - $1.59 Million
-24,875 Reduced 20.21%
98,234 $5.78 Million
Q1 2020

Apr 28, 2020

SELL
$46.4 - $67.43 $67,233 - $97,706
-1,449 Reduced 1.16%
123,109 $6.86 Million
Q4 2019

Jan 27, 2020

SELL
$49.21 - $64.19 $1.08 Million - $1.41 Million
-21,951 Reduced 14.98%
124,558 $8 Million
Q3 2019

Nov 13, 2019

BUY
$42.77 - $50.71 $758,825 - $899,696
17,742 Added 13.78%
146,509 $7.43 Million
Q3 2019

Oct 24, 2019

SELL
$42.77 - $50.71 $780,210 - $925,051
-18,242 Reduced 12.41%
128,767 $7.99 Million
Q2 2019

Jul 23, 2019

BUY
$44.62 - $49.34 $359,547 - $397,581
8,058 Added 5.8%
147,009 $6.67 Million
Q1 2019

May 07, 2019

SELL
$45.12 - $53.8 $344,761 - $411,085
-7,641 Reduced 5.21%
138,951 $6.63 Million
Q4 2018

Jan 31, 2019

SELL
$48.76 - $63.23 $3.02 Million - $3.91 Million
-61,840 Reduced 29.67%
146,592 $7.62 Million
Q3 2018

Oct 29, 2018

SELL
$55.19 - $62.25 $914,995 - $1.03 Million
-16,579 Reduced 7.37%
208,432 $0
Q2 2018

Aug 08, 2018

BUY
$50.53 - $62.98 $7,478 - $9,321
148 Added 0.07%
225,011 $12.5 Million
Q1 2018

May 08, 2018

SELL
$59.92 - $68.98 $1.98 Million - $2.28 Million
-33,054 Reduced 12.82%
224,863 $14.2 Million
Q4 2017

Feb 08, 2018

SELL
$59.94 - $65.35 $439,000 - $478,623
-7,324 Reduced 2.76%
257,917 $15.8 Million
Q3 2017

Nov 13, 2017

SELL
$55.23 - $63.74 $2.99 Million - $3.45 Million
-54,074 Reduced 16.93%
265,241 $16.9 Million
Q2 2017

Aug 10, 2017

BUY
N/A
319,315
319,315 $17.8 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hgk Asset Management Inc Portfolio

Follow Hgk Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hgk Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hgk Asset Management Inc with notifications on news.